SPOTLIGHT -
Zeiss Vision unveils ClearView Single Vision lenses
The lens giant pairs precision vision of freeform-optimized lenses with the cost benefit of standard single vision lenses.
Harrow enters agreement to acquire exclusive US rights to suite of Novartis products
In the second deal between Harrow and Novartis, the former is expected to add 5 ophthalmic products to its portfolio.
EyeCon 2022: Ensuring your patients receive thorough presbyopic care
Marc R. Bloomenstein, OD, FAAO, shares key takeaways from his EyeCon 2022 presentation, "Advances in presbyopia."
Creating an inclusive and equitable workspace
Ruth Shoge, OD, MPH, FAAO, shares key takeaways from her EyeCon 2022 presentation, "Diversity in practice, creating an inclusive and equitable workspace."
2022 brought pipeline advances in glaucoma, retina, cornea, and beyond
Justin Schweitzer, OD, gives a brief overview of his EyeCon 2022 presentations, reflecting on pipeline advancements made in optometry in 2022.
EyeCon 2022: Improve your practice with these industry innovations
Adam Ramsey, OD, shares key takeaways from his EyeCon 2022 presentation, "Advances in industry innovations to improve your practice."
EyeCon 2022: Advances in presbyopia
Mile Brujic, OD, FAAO, shares key takeaways from his EyeCon 2022 presentation, "Advances in presbyopia."
EyeCon 2022: The past, present, and future of contact lens technology
Lyndon Jones, BSc, PhD, DSc, FCAHS, FCOptom, DipCLP, DipOrth, FAAO, FIACLE, FBCLA , shares key takeaways from his EyeCon 2022 presentation, "Advances in presbyopia."
FDA approves latanoprost ophthalmic solution from Thea for reduction of IOP
As the first and only preservative-free formulation of latanoprost, IYUZEH 0.005% is approved to reduce IOP in patients with open-angle glaucoma or ocular hypertension.
EyeCon 2022: Diversity, equity, and inclusion in your optometry practice
Adam Ramsey, OD, shares key takeaways from his presentation on diversity, equity, and inclusion in you optometry practice, which he presented during EyeCon 2022.
FDA grants 510(k) clearance to Bausch + Lomb for Biotrue® Hydration Boost contact lens rehydrating drops
The preservative-free, multi-dose contact lens rehydrating drops are expected to hit the market in early 2023.
Ocuphire submits new drug application for eye drops for reversal of mydriasis
The submission is supported by positive phase 3 data, which shows quick reversal of dilation and favorable safety and tolerability.
President of Verséa outlines new ophthalmic tech
Rob Sambursky, MD, president of Verséa Ophthalmics, sat down with David Hutton of Ophthalmology Times to discuss 3 major developments in the company pipeline.
EyeCare4Kids launches #GlassesOn campaign to contribute to underserved communities
The #GlassesOn campaign promotes the benefits of eyewear for kids and invites support for the non-profit through Giving Tuesday on November 29th.
Ocuphire initiates Global License Agreement for Nyxol eye drops across 3 indications
Ocuphire seeks to develop and commercialize Nyxol for the reversal of mydriasis, presbyopia and night vision disturbances.
Apellis aims to submit 24-month Phase 3 data to FDA for pegcetacoplan NDA
The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.